Therapeutic targeting of vegf and/or tgf-β to enhance anti-pd-(l)1 therapy: the evidence from clinical trials

HIGHLIGHTS

• who: Linwei Li from the University of Bari Aldo Moro, Italy have published the article: Therapeutic targeting of VEGF and/or TGF-u03b2 to enhance anti-PD-(L)1 therapy: The evidence from clinical trials, in the Journal: (JOURNAL) of 15/09/2021
• what: For safety, this study showed that the combination of sunitinib or pazopanib and nivolumab caused a high incidence of toxicities which limited the future use of either combination regimen . This study demonstrated that pembrolizumab plus axitinib could be used as first-line treatment for ccRCC . The study showed that the ORR . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.